Cost-effective diagnostics for cancer? Only with VolitionRx!

24/06/2016 - 1 minute

Aberdeen, we say goodbye to you!

We’re leaving Scotland this week and are heading down to Belgium. Besides being the place where most of the European Union action happens, Belgium also has a strong and interesting biotech scene. That’s why in Namur we’re visiting VolitionRx, our Biotech of the Week.


City: Namur (Belgium)

Founded: 2010

Employees: 11-50 employees 

Related Content

Financial Data: €77M

CEO: Cameron Reynolds


Mission: VolitionRx wants to address the need for non-invasive, accurate, and cost-effective diagnostics for cancer and other conditions.

Founded in 2010, VolitionRx brings together ELISA diagnostics (a long established method to identify proteins) with cutting-edge nucleosome detection and analysis techniques.

The resulting test takes less than a drop of blood and can measure and analyze nucleosomes (a basic unit of ‘packed’ DNA), which are often irregular in diseases like cancer.

Related Content

Comment: The market cap of VolitionRx is over €78M,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member